Interpreting journal articles: How to validate, apply results
March 1st 2008It is incredibly tempting for readers to immediately look at the results of a study and determine the conclusions; however, the evidence-based mindset requires a more rational approach that questions the validity of the results, followed by a close inspection of them.
PIN or atypical foci suspicious for PCa on biopsy: Risks and recommendations
March 1st 2008About 10% of needle biopsy reports will be returned with a diagnosis of prostatic intraepithelial neoplasia (PIN) or of "atypical" cells that are possibly indicative of carcinoma. Armed with knowledge of the likelihood of each of these diagnoses developing into cancer over time, urologists can avoid subjecting patients to unnecessary repeat biopsies.
Botulinum toxin may trigger severe adverse reactions
February 28th 2008FDA has received reports of systemic adverse reactions, including respiratory compromise and death following the use of botulinum toxins types A (Botox) and B (BotoMyobloc) for FDA-approved and unapproved uses. The reactions reported are suggestive of botulism, the agency said.
Androgen-independent prostate Ca more likely to metastasize
February 28th 2008Prostate cancers that are resistant to androgen deprivation therapy are more invasive and are more likely to spread to other organs than are androgen-dependent prostate cancers, according to UCLA researchers. The findings could change the way some prostate cancers are treated, spurring earlier use of hormone therapy to prevent the cancer’s spread, said senior author Robert Reiter, MD.
PSA testing can predict advanced prostate cancer
February 28th 2008A single PSA test taken before the age 50 years can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a study by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden. The findings, published in the online journal BMC Medicine, should help physicians identify men who would benefit from intensive prostate cancer screenings over their lifetime.
NIH: Urinary incontinence stigma still hampers treatment
February 28th 2008An independent panel convened by the National Institutes of Health found that fewer than half of those experiencing urinary or fecal incontinence report their symptoms to health care providers without prompting, impairing their quality of life and hindering development of prevention and treatment strategies.
Evidence 'insufficient' for routine prostate cancer screening
February 28th 2008The American College of Preventive Medicine has found there is insufficient evidence to recommend for or against routine population prostate cancer screening with digital rectal examination or PSA. The college has issued a practice policy statement advising clinicians caring for men, particularly African-American men and those with a family history of prostate cancer, to provide them with information about the potential benefits and harms of screening and the limits of current evidence to allow these patients to make an informed decision about screening (Am J Prev Med 2008; 34:164-70).
Dr. Gill named chairman of Cleveland Clinic urology department
February 14th 2008Inderbir Gill, MD, has been appointed chairman of the department of urology at the Cleveland Clinic. The department of urology is one of three departments within the new Glickman Urological and Kidney Institute, along with the department of regional urology and the department of nephrology and hypertension.
Vaccine prevents prostate cancer development in mice
February 14th 2008Researchers at the University of Southern California, Los Angeles, have developed a prostate cancer vaccine that prevented the development of cancer in 90% of young mice genetically predestined to develop the disease, and suggest the same strategy might work for men with rising levels of PSA (Cancer Res 2008; 68:861-9).
Urinary dysfunction is most troubling side effect after RP
February 14th 2008Men with prostate cancer who undergo prostatectomy cite sexual dysfunction as the most common side effect after surgery, but urinary dysfunction troubles these patients most, a study from the University of Florida College of Nursing, Gainesville, has found. What’s more, many are not emotionally prepared to face these complications, according to the study, reported in Urologic Nursing (2007; 27:527-33).
Dietary supplements may promote prostate cancer progression
February 14th 2008Hormonal components in over-the-counter dietary supplements may promote the progression of prostate cancer and decrease the effectiveness of anti-cancer drugs, report researchers at the University of Texas Southwestern Medical Center, Dallas. The findings, which appear in Clinical Cancer Research (2008; 14:607-11), reaffirm that patients should inform their doctors about any herbal or hormonal dietary supplements they are taking or are considering taking.
Effectiveness, harms of prostate Ca treatments: Data are limited
February 14th 2008Assessing the comparative effectiveness and harms of various treatments for localized prostate cancer treatments is difficult because of limitations in evidence, according to a study to be published in the March 18, 2008, edition of the Annals of Internal Medicine.
Biological factors may drive tumor aggressiveness in African-Americans
February 14th 2008Researchers analyzing prostate tumors have identified differences in gene expression between African-American and Caucasian men that show the existence of distinct tumor microenvironments in these two patient groups. The study, conducted by investigators at the National Cancer Institute, Bethesda, MD, appears in Cancer Research (2008; 68:927-36).